The Technical Analyst
Dare Bioscience Inc [DARE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Dare Bioscience Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.56% $0.300
America/New_York / 23 apr 2024 @ 12:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 30.16 mill |
| EPS: | -0.350 |
| P/E: | -0.860 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 100.58 mill |
| Avg Daily Volume: | 0.445 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.860 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.860 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0871 (-70.96%) $-0.213 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.254 - 0.346 ( +/- 15.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-12 | Fair John A | Buy | 290 000 | Employee Stock Option (right to buy) |
| 2024-03-12 | Johnson Sabrina Martucci | Buy | 750 000 | Employee Stock Option (right to buy) |
| 2024-03-12 | Haring-layton Mardee | Buy | 290 000 | Employee Stock Option (right to buy) |
| 2024-01-26 | Haring-layton Mardee | Sell | 3 500 | Employee Stock Option (right to buy) |
| 2024-01-26 | Haring-layton Mardee | Sell | 30 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 78.81 |
| Last 91 transactions |
| Buy: 10 072 923 | Sell: 492 500 |
Forecast:
14:37 - $0.305
Live Trading Signals (every 1 min)
Forecast
1: 13:07 - $0.300
Forecast 2: 13:57 - $0.297
Forecast 3: 14:37 - $0.305
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.300 (1.56% ) |
| Volume | 0.266 mill |
| Avg. Vol. | 0.445 mill |
| % of Avg. Vol | 59.81 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DARE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DARE
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
Latest Press Releases
2024-04-23 08:00:00 - Press Release
DarÉ Bioscience Announces Grant Funding Installment To Support Further Development Of Novel Contraceptive Technology Dare-larc1
Daré bioscience's dare-larc1 platform technology has transformative potential for women's health as well as in treating a broad range of diseases
2024-04-11 08:00:00 - Press Release
DarÉ Bioscience Announces Publication In Contraception Of Positive Efficacy And Safety Findings From A Pre-pivotal Postcoital Test Study Of Ovaprene®: An Investigational Hormone-free Monthly Intravaginal Contraceptive
Published data shows that ovaprene was safe and effective in a postcoital test study of 33 women pivotal phase 3 contraceptive efficacy clinical study of ovaprene currently enrolling ovaprene has the potential to be the first fda-approved hormone-free monthly intravaginal contraceptive for women san diego, april 11, 2024 (globe newswire) -- darÉ bioscience, inc. (nasdaq: dare), a leader in women's health innovation, today announced the publication of data from the postcoital test clinical study of ovaprene in two original research articles in the journal contraception. publication details: mauck, et al.
2024-03-28 08:00:00 - Press Release
DarÉ Bioscience Reports Full Year 2023 Financial Results And Provides Company Update
2023 highlights and anticipated 2024 milestones xaciato™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the united states to treat bacterial vaginosis under license agreement with commercial collaborator organon ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal phase 3 contraceptive efficacy study recruiting across the united states sildenafil cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder successful completion of end-of-phase 2 meeting with fda; forthcoming additional fda feedback; phase 3 design, development, and collaboration strategy updates san diego, march 28, 2024 (globe newswire) -- darÉ bioscience, inc...
2024-03-21 08:00:00 - Press Release
DarÉ Bioscience To Host Full Year 2023 Financial Results And Company Update Conference Call And Webcast On March 28, 2024
San diego, march 21, 2024 (globe newswire) -- darÉ bioscience, inc. (nasdaq: dare), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. eastern time on thursday, march 28, 2024, to review its financial results for the year ended december 31, 2023 and to provide a company update.
2024-01-31 08:00:00 - Press Release
Daré Bioscience Announces Positive End-of-phase 2 Meeting With Fda On Development Of Sildenafil Cream, 3.6% In Female Sexual Arousal Disorder And Provides Company Focus Areas For 2024
There are no fda-approved treatments for female sexual arousal disorder there are no fda-approved treatments for female sexual arousal disorder
Latest News
2024-03-28 20:47:08 - Seeking Alpha
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
2024-03-21 08:00:00 - GlobeNewsWire
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update.
2023-11-09 21:56:04 - Seeking Alpha
Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Conference Call Participants Catherine Novack - Jones Trading Doug Tsao - H.C. Wainright Operator Welcome to the conference hosted by Daré Bioscience to Review the Company's Third Quarter Financial Results and to provide a General Business Update.
2023-08-03 08:00:00 - GlobeNewsWire
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update.
2023-07-13 16:26:06 - Proactive Investors
Daré Bioscience's 'female Viagra' could be first-in-category product: broker
Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The women's health-focused biopharmaceutical company on Tuesday reported positive results from its Phase 2b RESPOND study evaluating its proprietary topical formulation of sildenafil (sildenafil cream 3.6%) as a treatment for female sexual arousal disorder (FSAD), a condition for which there is no Food and Drug Administration (FDA)-approved treatment.
2023-07-11 17:30:00 - GlobeNewsWire
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.
2023-05-11 22:10:22 - Seeking Alpha
Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Commercial Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Call Participants Catherine Novack – Jones Research Kumar Raja – ROTH Capital Kemp Dolliver – Brookline Capital Markets Doug Tsao – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended March 31, 2023, and to provide a General Business Update.
2023-05-04 08:00:00 - GlobeNewsWire
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter ended March 31, 2023 and to provide a Company update.
2023-03-30 23:16:05 - Seeking Alpha
Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript
Dare Bioscience, Inc. (NASDAQ:DARE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright Kumaraguru Raja - ROTH Capital Joanne Lee - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company's Financial Results for the Year Ended December 31, 2022 and to provide a general business update.
2023-03-23 08:00:00 - GlobeNewsWire
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update.